ライフサイエンスコーパス: herpes zoster

1 ter reactivate to cause a secondary disease (herpes zoster).

2 n postvaccination GMT and risk of subsequent herpes zoster.

3 ntion of VZV reactivation and development of herpes zoster.

4 ls >/= 60 years old with a recent episode of herpes zoster.

5 ith a recent episode of clinically diagnosed herpes zoster.

6 n sensory neurons from reactivating to cause herpes zoster.

7 ine was associated with a lower incidence of herpes zoster.

8 ccination remained highly protective against herpes zoster.

9 as 100% (95% CI, 67%-100%; P < .001) against herpes zoster.

10 t to valacyclovir for the treatment of acute herpes zoster.

11 e its clinical efficacy for the treatment of herpes zoster.

12 al copies correlated with the progression of herpes zoster.

13 ts that viremia is a common manifestation of herpes zoster.

14 at >1 variant strain may reactivate to cause herpes zoster.

15 luded meningitis in patients with concurrent herpes zoster.

16 in a long-term-care facility after a case of herpes zoster.

17 fer to skin in the affected dermatome during herpes zoster.

18 the often severe neurologic consequences of herpes zoster.

19 anglia and reactivates from latency to cause herpes zoster.

20 tency in sensory ganglia, and reactivates as herpes zoster.

21 at patients with RA are at increased risk of herpes zoster.

22 rticosteroids appeared to be associated with herpes zoster.

23 n alphaherpesvirus that causes varicella and herpes zoster.

24 h a median of 3.12 years of surveillance for herpes zoster.

25 VZV reactivation results in herpes zoster.

26 on for development of treatments for painful herpes zoster.

27 al latency, and can reactivate, resulting in herpes zoster.

28 tiviral therapy in the management of pain of herpes zoster.

29 12,819 for primary varicella and $15,583 for herpes zoster.

30 ensory ganglia, and can re-activate to cause herpes zoster.

31 evere morbidity due to primary varicella and herpes zoster.

32 tient had a documented infection, dermatomal herpes zoster.

33 hat is the causative agent of chickenpox and herpes zoster.

34 therapeutic options for treating adults with herpes zoster.

35 strategy with which to modify the course of herpes zoster.

36 s a highly contagious agent of varicella and herpes zoster.

37 VZV) is the causative agent of varicella and herpes zoster.

38 ia and can reactivate later in life to cause herpes zoster.

39 are transiently increased after exposure to herpes zoster.

40 isk of acute cardiovascular events following herpes zoster.

41 duals in comparison with patients with acute herpes zoster.

42 en chronic obstructive pulmonary disease and herpes zoster.

43 a small but significantly increased risk of herpes zoster.

44 geminal ganglion, in the absence of clinical herpes zoster.

45 ociation between statin use and incidence of herpes zoster.

46 Among 251 patients with herpes zoster, 14 had the vaccine strain of varicella zo

47 ced transient local skin reactions: 1 (4.8%) herpes zoster, 3 (14.3%) transaminase elevation, and 1 (

48 A total of 957 confirmed cases of herpes zoster (315 among vaccine recipients and 642 amon

49 Regarding herpes zoster, 66.9% of patients were aged >64 years, an

50 nd 31.5% in the 5.25-mg group, vs. 1.8%) and herpes zoster (8 patients and 12 patients, respectively,

51 y end point was the burden of illness due to herpes zoster, a measure affected by the incidence, seve

52 relates ZV-induced antibody and the risk of herpes zoster, a protective threshold was not determined

53 1.04; 95% confidence interval 1.00-1.08) or herpes zoster (adjusted HR 1.03; 95% confidence interval

54 Reactivation of VZV causes herpes zoster, also known as shingles.

55 Rates of herpes zoster among patients with RA and randomly sample

56 confirmed cases, the incidence of recurrent herpes zoster among persons aged <70 years was 0.99 (95%

57 ecified analysis, we found a similar risk of herpes zoster among statin users in the subgroup of pati

58 e subjects, 1 DZB(-)MMF(-) subject developed herpes zoster and 1 DZB(-)MMF(+) subject had Bell's pals

59 equivalent to about 17 000 fewer episodes of herpes zoster and 3300 fewer episodes of postherpetic ne

60 a vaccine effectiveness of about 62% against herpes zoster and 70-88% against postherpetic neuralgia.

61 ine is being developed for the prevention of herpes zoster and its complications.

62 ster vaccine markedly reduced morbidity from herpes zoster and postherpetic neuralgia among older adu

63 decrease the incidence, severity, or both of herpes zoster and postherpetic neuralgia among older adu

64 o estimate vaccine coverage and incidence of herpes zoster and postherpetic neuralgia consultations.

65 es zoster vaccine is effective in preventing herpes zoster and postherpetic neuralgia in immunocompet

66 diagnosis, natural history, and treatment of herpes zoster and postherpetic neuralgia in immunocompet

67 of the vaccination programme on incidence of herpes zoster and postherpetic neuralgia in this populat

68 The incidence and severity of herpes zoster and postherpetic neuralgia increase with a

69 ultations with patients aged 60-89 years for herpes zoster and postherpetic neuralgia occurring betwe

70 cinations administered and consultations for herpes zoster and postherpetic neuralgia, and aggregated

71 osting VZV-CMI protects older adults against herpes zoster and postherpetic neuralgia.

72 ce-attenuated vaccine against chickenpox and herpes zoster and providing a new target for interventio

73 st (>5%) for oral candidiasis, tuberculosis, herpes zoster, and bacterial pneumonia.

74 e zoster, unit cost of the vaccine, risk for herpes zoster, and duration of vaccine efficacy.

75 neumonia, hepatitis, meningitis, septicemia, herpes zoster, and poliomyelitis), and inflammatory (glo

76 To examine whether herpes zoster antigen (also called varicella-zoster viru

77 Herpes zoster antigen was detected in 3 of 25 temporal a

78 ups of patients, false-positive staining for herpes zoster antigen was detected in the presence of ca

79 False-positive staining for herpes zoster antigen was detected on several temporal a

80 Among the GCA-negative group, herpes zoster antigen was not detected in any biopsy.

81 group, 3 patients had positive staining for herpes zoster antigen.

82 ential approaches to improving prevention of herpes zoster are discussed.

83 he motivating study above, the odds ratio of herpes zoster associated with chronic obstructive pulmon

84 r virus is an important human pathogen, with herpes zoster being a major health issue in the aging an

85 eased incidences of cytomegalovirus disease, herpes zoster, BK virus, and nephropathy, which led to t

86 cent (P<0.001), and reduced the incidence of herpes zoster by 51.3 percent (P<0.001).

87 vaccine reduced the burden of illness due to herpes zoster by 61.1 percent (P<0.001), reduced the inc

88 ent varicella-zoster virus infection against herpes zoster by boosting immunity is not known.

89 is commonly thought to increase the risk of herpes zoster by causing immunosuppression.

90 Herpes zoster can be associated with a variety of neurol

91 n environmental samples from the room of the herpes zoster case patient.

92 The number of herpes zoster cases among vaccinated individuals was 828

93 users of anti-TNF therapy, we identified 310 herpes zoster cases.

94 PHN) is the most significant complication of herpes zoster caused by reactivation of latent Varicella

95 port the first laboratory-documented case of herpes zoster caused by the attenuated varicella zoster

96 reased rate of Coccidioides, Salmonella, and herpes zoster compared to children with ADHD.

97 stroke and acute MI in defined periods after herpes zoster compared to other time periods, within ind

98 ted with a significantly higher incidence of herpes zoster compared with dexamethasone treatment (13%

99 nti-TNF therapies were not at higher risk of herpes zoster compared with patients who initiated nonbi

100 from the most commonly used method to obtain herpes zoster data (rates obtained from administrative d

101 Medicare beneficiaries aged >/= 65 y with a herpes zoster diagnosis and either an ischemic stroke (n

102 Risk of herpes zoster differed by vaccination status to a greate

103 c neuralgia is the most important symptom of herpes zoster disease and it is very difficult to treat.

104 c neuralgia is the most important symptom of herpes zoster disease, which is caused by Varicella zost

105 of 17 VZV-seropositive patients experienced herpes zoster during the posttransplant period.

106 ng immunocompetent patients who had a recent herpes zoster episode.

107 for the three routine cohorts, incidence of herpes zoster fell by 35% (incidence rate ratio 0.65 [95

108 The adjusted hazard ratios of herpes zoster for patients with RA compared with non-RA

109 ars of age or older reduced the incidence of herpes zoster from 11.12 to 5.42 cases per 1000 person-y

110 activation in the peripheral nervous system (herpes zoster) have been published, while exceedingly fe

111 nation was associated with a reduced risk of herpes zoster (hazard ratio [HR], 0.45; 95% CI, 0.42-0.4

112 CI, 0.23-0.61) and hospitalizations coded as herpes zoster (HR, 0.35; 95% CI, 0.24-0.51) were less li

113 Ophthalmic herpes zoster (HR, 0.37; 95% CI, 0.23-0.61) and hospital

114 ological agent of varicella (chickenpox) and herpes zoster (HZ [shingles]).

115 ive agent of both varicella (chickenpox) and herpes zoster (HZ) (shingles).

116 Herpes zoster (HZ) adversely affects individuals aged 50

117 Each year, herpes zoster (HZ) affects 1 million U.S. adults, many o

118 Worldwide, herpes zoster (HZ) affects millions of patients (particu

119 es have shown a decrease in the incidence of herpes zoster (HZ) among human immunodeficiency virus (H

120 Tens of millions of seniors are at risk of herpes zoster (HZ) and its complications.

121 Herpes zoster (HZ) and postherpetic neuralgia (PHN) caus

122 icians' perception of burden associated with herpes zoster (HZ) and postherpetic neuralgia (PHN), int

123 humoral and cell-mediated immunity (CMI) to herpes zoster (HZ) and protection against HZ morbidity a

124 Risk factors for herpes zoster (HZ) are poorly defined.

125 n LTPS decreased from 61.1% to 37.3% for the herpes zoster (HZ) burden of illness (BOI), from 66.5% t

126 Vaccine efficacy for herpes zoster (HZ) burden of illness, incidence of posth

127 Vaccine-strain herpes zoster (HZ) can occur after varicella vaccination

128 lined following varicella vaccine licensure, herpes zoster (HZ) cases may play a larger role in varic

129 varicella vaccination on the epidemiology of herpes zoster (HZ) critically depends on the mechanism o

130 on emergency department (ED) utilization for herpes zoster (HZ) has not been examined to date.

131 Temporal increases in the incidence of herpes zoster (HZ) have been reported but studies have e

132 A vaccine to prevent herpes zoster (HZ) in adults > or =60 years of age with

133 troviral therapy (HAART) on the incidence of herpes zoster (HZ) in human immunodeficiency virus (HIV)

134 The risk for herpes zoster (HZ) in patients with psoriasis treated wi

135 ination program might lead to an increase in herpes zoster (HZ) incidence has been supported by model

136 The incidence and severity of herpes zoster (HZ) increases with age.

137 Protection against herpes zoster (HZ) induced by the live attenuated zoster

138 Herpes zoster (HZ) is a frequent complication of advance

139 Herpes zoster (HZ) is common and often severe in patient

140 ostherpetic neuralgia (PHN) risk by reducing herpes zoster (HZ) occurrence, it is less clear whether

141 e in a healthy population, the protection of herpes zoster (HZ) vaccine in end-stage renal disease (E

142 Based on limited data, the live attenuated herpes zoster (HZ) vaccine is contraindicated in patient

143 Understanding long-term effectiveness of herpes zoster (HZ) vaccine is critical for determining v

144 Herpes zoster (HZ) vaccine was recommended in the United

145 Recombinant herpes zoster (HZ) vaccines may be an alternative to the

146 nfected individuals are at increased risk of herpes zoster (HZ), even in the antiretroviral therapy (

147 cine recipients with postvaccination rash or herpes zoster (HZ), focusing on polymorphisms between li

148 mmunologic factors that modulate the risk of herpes zoster (HZ), we compared varicella-zoster virus (

149 ster virus and thereby increase incidence of herpes zoster (HZ).

150 and decreases the incidence and severity of herpes zoster (HZ).

151 vaccine in older adults following documented herpes zoster (HZ).

152 ection, as well as reactivation resulting in herpes zoster (HZ).

153 , establish latency, and reactivate to cause herpes zoster (HZ).

154 from which it can later reactivate to cause herpes zoster (HZ).

155 healthy individuals >60 years of age against herpes zoster (HZ).

156 he life of the host, may reactivate to cause herpes zoster (HZ).

157 kenpox and reactivation of latent VZV causes herpes zoster (HZ).

158 ency, and in rare cases, reactivate to cause herpes zoster (HZ).

159 ine efficacy (VE) to reduce the incidence of herpes zoster (HZ).

160 ological agent of varicella (chickenpox) and herpes zoster (HZ, shingles).

161 After herpes zoster, immunocompetent persons frequently experi

162 g of oral acyclovir reduces the incidence of herpes zoster in a randomized, double-blind, placebo-con

163 ated varicella-zoster virus vaccine prevents herpes zoster in adults older than 50 years.

164 su vaccine significantly reduced the risk of herpes zoster in adults who were 50 years of age or olde

165 1 g TID versus 2 g TID, for the treatment of herpes zoster in immunocompromised patients > or =18 yea

166 psychologic stress on the risk of acquiring herpes zoster in late life were examined.

167 aricella-zoster virus vaccination to prevent herpes zoster in older adults would increase QALYs compa

168 mpared with placebo, in reducing the risk of herpes zoster in older adults.

169 billing code data identified 1,959 cases of herpes zoster in Olmsted County, Minnesota, adults betwe

170 , educate, and prescribe the vaccine against herpes zoster in order to increase utilization of this v

171 three serious infections, and four cases of herpes zoster in patients who received tofacitinib durin

172 f hospitalization with primary varicella and herpes zoster in the prevaccine era and the usefulness o

173 of vaccine efficacy offset a lower risk for herpes zoster in the younger group.

174 tios for the incidence rates of varicella or herpes zoster in vaccinated versus unvaccinated children

175 acyclovir prophylaxis significantly reduced herpes zoster incidence among HIV-infected persons.

176 Accurate rates of herpes zoster incidence and complication have become of

177 models to compare propensity score-adjusted herpes zoster incidence between new anti-TNF and nonbiol

178 We compared herpes zoster incidence between new anti-TNF users (n=33

179 Herpes zoster incidence increases with bortezomib.

180 MAIN OUTCOME MEASURES: Herpes zoster incidence rate within 42 days after vaccin

181 ; IRR 3.8 [95% CI 1.2-9.5]), and 32 cases of herpes zoster (incidence rate 225 per 100,000 person-yea

182 on for the four catch-up cohorts was 33% for herpes zoster (incidence rate ratio 0.67 [0.61-0.74]) an

183 Neurologic complications of herpes zoster, including chronic encephalitis, occur wit

184 that is the causative agent of varicella and herpes zoster, induces formation of the NLRP3 inflammaso

185 nine aminotransferase (29 [8%] vs six [2%]), herpes zoster infection (nine [3%] vs three [1%]), hyper

186 and is associated with an increased risk of herpes zoster infection in recipients of hematopoietic s

187 Disproportionality in reporting herpes zoster infection was higher for patients receivin

188 Herpes zoster infection was reported in 6% of patients i

189 oups, and the rates of overall infection and herpes zoster infection were higher with tofacitinib tha

190 ve fibre density, comparable to that seen in herpes zoster infection.

191 obronchitis and subsequently had a localized Herpes zoster infection.

192 mucositis, infections in the first 30 d, and herpes zoster infections in the first year after hematop

193 % CI, 2.26-2.91]); the proportion of serious herpes zoster infections was not higher than the proport

194 Most herpes zoster infections were grade 1/2; incidences of g

195 s, there were four serious infections, three herpes zoster infections, one myocardial infarction, and

196 a; recurrent, severe herpes simplex virus or herpes zoster infections; extensive and persistent infec

197 95% confidence interval [CI], 1.79-2.56), 77 herpes zoster (IR, 1.11; 95% CI, 0.88-1.39), 57 dermatop

198 -12.0; bacteremia, IR, 3.3; 95% CI, 2.9-3.8; herpes zoster, IR, 2.9; 95% CI, 2.6-3.3; disseminated M

199 Herpes zoster is a common late complication of varicella

200 s with rheumatoid arthritis (RA) and whether herpes zoster is associated with use of disease-modifyin

201 Herpes zoster is common and can have serious consequence

202 Herpes zoster is common and has serious consequences, no

203 Herpes zoster is common and vaccine preventable.

204 To determine whether the incidence of herpes zoster is elevated in patients with rheumatoid ar

205 protein E (gE) subunit vaccine candidate for herpes zoster is in development.

206 her research comparing antiviral efficacy in herpes zoster is needed.

207 Herpes zoster is still the most common viral infection i

208 owever, whether statins increase the risk of herpes zoster is unknown.

209 s vaccine in preventing varicella-zoster and herpes zoster is well documented, as are many of the mut

210 petic eye disease (due to herpes simplex and herpes zoster) is a significant cause of visual impairme

211 ren and young adults, potentially leading to herpes zoster later in life on reactivation from latency

212 DNA from a biopsy specimen of a chronic herpes-zoster lesion indicated that the Oka vaccine stra

213 Serious adverse events included herpes zoster (n = 2), influenza, and pneumonia.

214 Diabetes, infection (herpes zoster), nerve compression, nerve trauma, "channe

215 Approximately 1 million episodes of herpes zoster occur annually in the United States.

216 5175 person-years of follow-up, 26 cases of herpes zoster occurred among those assigned acyclovir, c

217 After inoculation, herpes zoster occurred in 7 vaccine recipients versus 24

218 sion, CsA nephrotoxicity, hyperuricemia, and Herpes zoster occurred statistically more frequently in

219 of biologic DMARDs alone was associated with herpes zoster (odds ratio [OR] 1.54, 95% CI 1.04-2.29),

220 ulopathy (2.3%), cranial nerve palsies (2%), herpes zoster ophthalmicus (HZO) (1.2%), and HIV retinop

221 ospital-based epidemiology study to describe herpes zoster ophthalmicus (HZO) prevalence and risk fac

222 Herpes zoster ophthalmicus (HZO), thought to be a unilat

223 st for prolonged periods on the cornea after herpes zoster ophthalmicus (HZO).

224 Herpes zoster ophthalmicus and scleritis/episcleritis IC

225 ical record can reliably be used to identify herpes zoster ophthalmicus cases.

226 s was noteworthy because the patient had had herpes zoster ophthalmicus diagnosed 3 weeks before the

227 Eyes with herpes zoster ophthalmicus had a significant (P<0.001) d

228 se of traditional DMARDs was associated with herpes zoster (OR 1.27, 95% CI 1.10-1.48).

229 ro mol/L) had a significantly higher risk of herpes zoster (OR: 6.6; 95% CI: 1.5, 29.6).

230 Herpes zoster prophylaxis is necessary with BDR, and rev

231 Only 11 patients (42%) had a concomitant herpes zoster rash.

232 = 1 for each) were grade 3 hyponatremia and herpes zoster reactivation and grade 4 neutropenia.

233 Herpes zoster reactivation disproportionately affects pa

234 No additional risk factors for herpes zoster reactivation were identified.

235 c agent of varicella (primary infection) and herpes zoster (reactivation of latent infection).

236 ion between vaccination and the incidence of herpes zoster recurrence among persons with a recent epi

237 The risk of herpes zoster recurrence following a recent initial epis

238 of oral corticosteroids was associated with herpes zoster regardless of concomitant therapies.

239 were similar between treatment arms, and no herpes zoster-related deaths occurred.

240 Among 697 herpes zoster reports, PCR analysis identified Oka VZV i

241 f the first seven treated patients developed herpes zoster, resulting in the institution of prophylac

242 necrosis factor (anti-TNF) therapy elevates herpes zoster risk.

243 o examine the effect of current treatment on herpes zoster risk.

244 Herpes zoster (shingles) causes significant morbidity in

245 he agent causing varicella (chicken pox) and herpes zoster (shingles), we generated a full-length inf

246 ZV) is the causative agent of chickenpox and herpes zoster (shingles).

247 the cause of both varicella (chickenpox) and herpes zoster (shingles).

248 between 5 and 40 years, it can give rise to herpes zoster (shingles).

249 ological agent of varicella (chickenpox) and herpes zoster (shingles).

250 Systemic antiviral medications for herpes zoster should be instituted within 72 hours of th

251 e immunogenicity and safety of an adjuvanted herpes zoster subunit (HZ/su) vaccine when coadministere

252 (HIV)-infected persons have higher rates of herpes zoster than HIV-uninfected individuals.

253 Men more frequently acquired herpes zoster than women, and men who developed hyporeti

254 recommendations for the analysis of pain in herpes zoster trials.

255 prednisone and two with CsA), and localized herpes zoster (two with IVCY).

256 lishes latency in sensory ganglia and causes herpes zoster upon reactivation.

257 INTERPRETATION: The herpes zoster vaccination programme in England has had a

258 In 2013, a herpes zoster vaccination programme was introduced in En

259 lysis: By reducing incidence and severity of herpes zoster, vaccination can increase quality-adjusted

260 We identified individual data on herpes zoster vaccinations administered and consultation

261 Live attenuated herpes zoster vaccine (HZV) reduces that risk, although

262 Herpes zoster vaccine (ZV) was administered as a second

263 Eighty-eight percent of providers recommend herpes zoster vaccine and 41% strongly recommend it, com

264 Physicians are making efforts to provide herpes zoster vaccine but are hampered by barriers, part

265 Efforts to facilitate the financing of herpes zoster vaccine could help increase its use.

266 Herpes zoster vaccine for persons aged 50 years does not

267 The licensing of herpes zoster vaccine has demonstrated that therapeutic

268 Of respondents who began administering herpes zoster vaccine in their office, 12% stopped becau

269 The herpes zoster vaccine is effective in preventing herpes

270 Only 45% of respondents knew that herpes zoster vaccine is reimbursed through Medicare Par

271 The herpes zoster vaccine is the most expensive vaccine reco

272 Herpes zoster vaccine is well tolerated in older, immuno

273 Single dose of herpes zoster vaccine or placebo.

274 Herpes zoster vaccine recipients were more likely to be

275 dults aged 60 years or older, receipt of the herpes zoster vaccine was associated with a lower incide

276 o speak English and Spanish who received the herpes zoster vaccine were compared with 66 patients who

277 ugh prelicensure data provided evidence that herpes zoster vaccine works in a select study population

278 wed, in addition to the effectiveness of the herpes zoster vaccine.

279 Overall vaccine efficacy against herpes zoster was 97.2% (95% confidence interval [CI], 9

280 Incidence of recurrent herpes zoster was compared between the vaccinated and th

281 During a mean follow-up of 3.2 years, herpes zoster was confirmed in 6 participants in the vac

282 Herpes zoster was diagnosed according to clinical and la

283 ost effectiveness of antiviral treatment for herpes zoster was estimated using these agents compared

284 Incidence of herpes zoster was evaluated in 663 patients with relapse

285 In the main analysis, the rate of herpes zoster was higher among users of statins relative

286 The case of herpes zoster was relatively mild and resolved without c

287 Herpes zoster was seen within 1 year after pentostatin i

288 An unrecognized case of herpes zoster was the likely source.

289 Annual hospitalizations for herpes zoster were 4-fold higher than for primary varice

290 l outcomes of myocardial infarction (MI) and herpes zoster were also studied.

291 The pain and discomfort associated with herpes zoster were measured repeatedly for six months.

292 e medical conditions, suggesting results for herpes zoster were not due to bias.

293 immunization and development of varicella or herpes zoster were noted.

294 patients with clinical evidence of localized herpes zoster were randomized to receive oral valacyclov

295 A total of 298 patients with herpes zoster were recruited as part of 2 community-base

296 Fifty-four patients with herpes zoster were treated with valacyclovir.

297 Serious or complicated cases of herpes zoster were uncommon.

298 Three months later he developed herpes zoster, which developed into chronic verrucous le

299 Reactivation from latency causes herpes zoster, which may be complicated by postherpetic

300 who had received varicella vaccine developed herpes zoster with meningitis.